text
stringlengths 985
288k
| stock_price_percentage_change
stringclasses 114
values | symbol
stringclasses 503
values | period
stringclasses 308
values |
|---|---|---|---|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2019-12-28 to 2020-01-03
[Next Week]: 2020-01-03 to 2020-01-10
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-03:
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
Quarter ending 2019-01-31 (FY 2019 Q1, currency: USD):
- Profitability: net margin 39.3%, operating margin 19.5%.
- Valuation: P/E 12.0x, P/B 4.8x, P/S 18.8x, P/FCF 139.0x.
- Balance sheet & liquidity: debt/equity 0.36, debt/assets 0.20, current ratio 3.39, quick ratio 2.79, cash ratio 1.88.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 16.6%, FCF / OCF 81.7%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2019-12-28 to 2020-01-03, A's stock price decreased from 85.95 to 84.57. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
4
|
A
|
2019-12-28 to 2020-01-10
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-01-04 to 2020-01-10
[Next Week]: 2020-01-10 to 2020-01-17
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-10:
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
Quarter ending 2019-01-31 (FY 2019 Q1, currency: USD):
- Profitability: net margin 39.3%, operating margin 19.5%.
- Valuation: P/E 12.0x, P/B 4.8x, P/S 18.8x, P/FCF 139.0x.
- Balance sheet & liquidity: debt/equity 0.36, debt/assets 0.20, current ratio 3.39, quick ratio 2.79, cash ratio 1.88.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 16.6%, FCF / OCF 81.7%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-01-04 to 2020-01-10, A's stock price increased from 84.82 to 87.59. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
3
|
A
|
2020-01-04 to 2020-01-17
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-01-11 to 2020-01-17
[Next Week]: 2020-01-17 to 2020-01-24
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-17:
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
Quarter ending 2019-01-31 (FY 2019 Q1, currency: USD):
- Profitability: net margin 39.3%, operating margin 19.5%.
- Valuation: P/E 12.0x, P/B 4.8x, P/S 18.8x, P/FCF 139.0x.
- Balance sheet & liquidity: debt/equity 0.36, debt/assets 0.20, current ratio 3.39, quick ratio 2.79, cash ratio 1.88.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 16.6%, FCF / OCF 81.7%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-01-11 to 2020-01-17, A's stock price increased from 87.46 to 90.12. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-2
|
A
|
2020-01-11 to 2020-01-24
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-01-18 to 2020-01-24
[Next Week]: 2020-01-24 to 2020-01-31
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-24:
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
Quarter ending 2019-01-31 (FY 2019 Q1, currency: USD):
- Profitability: net margin 39.3%, operating margin 19.5%.
- Valuation: P/E 12.0x, P/B 4.8x, P/S 18.8x, P/FCF 139.0x.
- Balance sheet & liquidity: debt/equity 0.36, debt/assets 0.20, current ratio 3.39, quick ratio 2.79, cash ratio 1.88.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 16.6%, FCF / OCF 81.7%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-01-18 to 2020-01-24, A's stock price decreased from 89.61 to 88.26. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-6
|
A
|
2020-01-18 to 2020-01-31
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-01-25 to 2020-01-31
[Next Week]: 2020-01-31 to 2020-02-07
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-31:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-01-25 to 2020-01-31, A's stock price decreased from 86.56 to 82.56. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
1
|
A
|
2020-01-25 to 2020-02-07
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-01 to 2020-02-07
[Next Week]: 2020-02-07 to 2020-02-14
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-02-07:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-02-01 to 2020-02-07, A's stock price increased from 82.15 to 83.17. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
3
|
A
|
2020-02-01 to 2020-02-14
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-08 to 2020-02-14
[Next Week]: 2020-02-14 to 2020-02-21
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-02-14:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-02-08 to 2020-02-14, A's stock price increased from 84.43 to 85.82. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-1
|
A
|
2020-02-08 to 2020-02-21
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-15 to 2020-02-21
[Next Week]: 2020-02-21 to 2020-02-28
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-02-21:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-02-15 to 2020-02-21, A's stock price increased from 84.79 to 85.07. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-9
|
A
|
2020-02-15 to 2020-02-28
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-22 to 2020-02-28
[Next Week]: 2020-02-28 to 2020-03-06
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-02-28:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-02-22 to 2020-02-28, A's stock price decreased from 80.50 to 77.07. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
2
|
A
|
2020-02-22 to 2020-03-06
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-29 to 2020-03-06
[Next Week]: 2020-03-06 to 2020-03-13
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-03-06:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-02-29 to 2020-03-06, A's stock price decreased from 81.97 to 78.56. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-12
|
A
|
2020-02-29 to 2020-03-13
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-03-07 to 2020-03-13
[Next Week]: 2020-03-13 to 2020-03-20
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-03-13:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-03-07 to 2020-03-13, A's stock price decreased from 70.75 to 69.20. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-4
|
A
|
2020-03-07 to 2020-03-20
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-03-14 to 2020-03-20
[Next Week]: 2020-03-20 to 2020-03-27
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-03-20:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-03-14 to 2020-03-20, A's stock price increased from 64.13 to 66.46. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
7
|
A
|
2020-03-14 to 2020-03-27
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-03-21 to 2020-03-27
[Next Week]: 2020-03-27 to 2020-04-03
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-03-27:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-03-21 to 2020-03-27, A's stock price increased from 63.37 to 70.91. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-1
|
A
|
2020-03-21 to 2020-04-03
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-03-28 to 2020-04-03
[Next Week]: 2020-04-03 to 2020-04-10
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-04-03:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-03-28 to 2020-04-03, A's stock price decreased from 72.67 to 70.42. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
11
|
A
|
2020-03-28 to 2020-04-10
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-04-04 to 2020-04-10
[Next Week]: 2020-04-10 to 2020-04-17
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-04-10:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-04-04 to 2020-04-10, A's stock price increased from 74.36 to 78.33. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
2
|
A
|
2020-04-04 to 2020-04-17
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-04-11 to 2020-04-17
[Next Week]: 2020-04-17 to 2020-04-24
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-04-17:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-04-11 to 2020-04-17, A's stock price increased from 76.21 to 79.55. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-5
|
A
|
2020-04-11 to 2020-04-24
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-04-18 to 2020-04-24
[Next Week]: 2020-04-24 to 2020-05-01
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-04-24:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-04-18 to 2020-04-24, A's stock price decreased from 77.37 to 75.75. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-2
|
A
|
2020-04-18 to 2020-05-01
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-04-25 to 2020-05-01
[Next Week]: 2020-05-01 to 2020-05-08
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-01:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-04-25 to 2020-05-01, A's stock price decreased from 76.25 to 74.21. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
7
|
A
|
2020-04-25 to 2020-05-08
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-02 to 2020-05-08
[Next Week]: 2020-05-08 to 2020-05-15
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-08:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-05-02 to 2020-05-08, A's stock price increased from 74.56 to 79.71. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
2
|
A
|
2020-05-02 to 2020-05-15
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-09 to 2020-05-15
[Next Week]: 2020-05-15 to 2020-05-22
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-15:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-05-09 to 2020-05-15, A's stock price increased from 81.27 to 81.59. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
4
|
A
|
2020-05-09 to 2020-05-22
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-16 to 2020-05-22
[Next Week]: 2020-05-22 to 2020-05-29
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-22:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-05-16 to 2020-05-22, A's stock price increased from 83.66 to 84.98. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
4
|
A
|
2020-05-16 to 2020-05-29
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-23 to 2020-05-29
[Next Week]: 2020-05-29 to 2020-06-05
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-29:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-05-23 to 2020-05-29, A's stock price increased from 86.13 to 88.14. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
3
|
A
|
2020-05-23 to 2020-06-05
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-30 to 2020-06-05
[Next Week]: 2020-06-05 to 2020-06-12
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-06-05:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-05-30 to 2020-06-05, A's stock price increased from 89.91 to 90.38. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-5
|
A
|
2020-05-30 to 2020-06-12
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-06-06 to 2020-06-12
[Next Week]: 2020-06-12 to 2020-06-19
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-06-12:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-06-06 to 2020-06-12, A's stock price decreased from 90.29 to 86.11. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
3
|
A
|
2020-06-06 to 2020-06-19
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-06-13 to 2020-06-19
[Next Week]: 2020-06-19 to 2020-06-26
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-06-19:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-06-13 to 2020-06-19, A's stock price increased from 86.96 to 88.73. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
-3
|
A
|
2020-06-13 to 2020-06-26
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-06-20 to 2020-06-26
[Next Week]: 2020-06-26 to 2020-07-03
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-06-26:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-06-20 to 2020-06-26, A's stock price decreased from 88.53 to 85.90. News during this period are listed below:
[News]:
- (2020-06-20 06:26) Zacks: Brokerages Expect Agilent Technologies Inc (NYSE:A) Will Post Earnings of $0.63 Per Share
Summary: Brokerages predict that Agilent Technologies Inc (NYSE:A) will report $0.65 earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have provided estimates for Agilent Technologies’ earnings, with estimates ranging from $0.49 to $0.73. Agilent Technologies reported earnings of $0.76 per share during the same quarter last year, which would suggest a […]
|
3
|
A
|
2020-06-20 to 2020-07-03
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-06-27 to 2020-07-03
[Next Week]: 2020-07-03 to 2020-07-10
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-03:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-06-27 to 2020-07-03, A's stock price increased from 87.29 to 88.68. News during this period are listed below:
[News]:
- (2020-06-28 10:56) Agilent Technologies Inc (NYSE:A) Declares $0.18 Quarterly Dividend
Summary: Agilent Technologies Inc (NYSE:A) declared a quarterly dividend on Wednesday, May 20th, Zacks reports. Investors of record on Tuesday, June 30th will be paid a dividend of 0.18 per share by the medical research company on Wednesday, July 22nd. This represents a $0.72 dividend on an annualized basis and a yield of 0.84%. The ex-dividend […]
- (2020-06-28 12:02) Agilent Technologies Inc (NYSE:A) Shares Sold by Skandinaviska Enskilda Banken AB publ
Summary: Skandinaviska Enskilda Banken AB publ reduced its position in Agilent Technologies Inc (NYSE:A) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 74,672 shares of the medical research company’s stock after selling 1,096 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s […]
- (2020-07-01 10:32) Agilent Technologies (NYSE:A) Stock Rating Reaffirmed by Goldman Sachs Group
Summary: Agilent Technologies (NYSE:A)‘s stock had its “neutral” rating reaffirmed by equities researchers at Goldman Sachs Group in a research report issued on Wednesday, Stock Target Advisor reports. Other equities research analysts have also recently issued research reports about the company. Cfra cut their target price on Agilent Technologies from $89.00 to $85.00 and set a […]
- (2020-07-01 11:54) Agilent Technologies Inc (NYSE:A) Holdings Cut by Guggenheim Capital LLC
Summary: Guggenheim Capital LLC cut its position in Agilent Technologies Inc (NYSE:A) by 31.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,478 shares of the medical research company’s stock after selling 23,802 shares during the quarter. Guggenheim Capital LLC’s holdings in Agilent Technologies […]
|
1
|
A
|
2020-06-27 to 2020-07-10
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-07-04 to 2020-07-10
[Next Week]: 2020-07-10 to 2020-07-17
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-10:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-07-04 to 2020-07-10, A's stock price increased from 89.31 to 89.42. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
6
|
A
|
2020-07-04 to 2020-07-17
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-07-11 to 2020-07-17
[Next Week]: 2020-07-17 to 2020-07-24
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-17:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-07-11 to 2020-07-17, A's stock price increased from 89.26 to 94.37. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
0
|
A
|
2020-07-11 to 2020-07-24
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-07-18 to 2020-07-24
[Next Week]: 2020-07-24 to 2020-07-31
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-24:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-07-18 to 2020-07-24, A's stock price decreased from 95.21 to 94.81. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
2
|
A
|
2020-07-18 to 2020-07-31
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-07-25 to 2020-07-31
[Next Week]: 2020-07-31 to 2020-08-07
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-31:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-07-25 to 2020-07-31, A's stock price decreased from 97.27 to 96.33. News during this period are listed below:
[News]:
- (2020-07-28 12:32) Ecolab : Second Quarter Reported Diluted Continuing Operations EPS $0.44; Adjusted Diluted Continuing Operations EPS $0.65, -49% | MarketScreener
- (2020-07-28 16:44) Charting a (bullish) holding pattern, S&P 500 digests break to 5-month highs
Summary: The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.
- (2020-07-29 19:50) These ‘green’ stocks would thrive under a Biden administration, according to fund managers
Summary: ‘Energy transformation will happen with or without politicians,’ says Jonathan Waghorn of the Guinness Atkinson Alternative Energy Fund.
- (2020-07-31 16:00) Craving Healthcare: A Beginner's Guide And My 7 Picks
Summary: The Healthcare sector has significantly outperformed the S&P 500 in the last decade and with lower volatility – the only sector to do so.
|
2
|
A
|
2020-07-25 to 2020-08-07
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-01 to 2020-08-07
[Next Week]: 2020-08-07 to 2020-08-14
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-08-07:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-08-01 to 2020-08-07, A's stock price decreased from 99.09 to 97.78. News during this period are listed below:
[News]:
- (2020-08-03 00:00) Samyang Biopharm USA Announces Hyun Jung Helen Lee, M.D., Named to PharmaVOICE 100
Summary: Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Biopharmaceuticals Corp. (https://samyangbiopha
- (2020-08-04 00:00) COVID-19 Impacts: Biotechnology Reagents Market Will Accelerate at a CAGR of about 8% through 2020-2024|Presence of High-Throughput and Novel Technologies to Boost Growth| Technavio
Summary: The Global Biotechnology Reagents Market will grow by USD 37.87 bn during 2020-2024
- (2020-08-04 06:40) Analysts Anticipate Agilent Technologies Inc (NYSE:A) Will Post Earnings of $0.54 Per Share
Summary: Analysts predict that Agilent Technologies Inc (NYSE:A) will report earnings of $0.54 per share for the current quarter, according to Zacks. Five analysts have made estimates for Agilent Technologies’ earnings, with the lowest EPS estimate coming in at $0.37 and the highest estimate coming in at $0.70. Agilent Technologies reported earnings per share of $0.76 […]
- (2020-08-04 16:38) Charting a solid August start: S&P 500, Nasdaq stage latest summer breakouts
Summary: Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish amid a solid August start, writes Michael Ashbaugh.
- (2020-08-04 18:43) STERIS plc (STE) CEO Walter Rosebrough on Q1 2021 Results - Earnings Call Transcript
Summary: STERIS plc (NYSE:STE) Q1 2021 Results Conference Call August 03, 2020 10:00 AM ET Company Participants Julie Winter - Investor Relations Walter Rosebrough - President and Chief Executive Officer Michael Tokich - Senior Vice President and Chief Financial Officer Daniel Carestio - Senior Vice President and Chief Operating Officer Conference Call Participants David Turkaly - JMP Securities Christopher Cooley - Stephens Inc Michael Matson - Needham and Company Lawrence Keusch - Raymond James Matthew Mishan - KeyBanc Capital Markets Presentation Operator Good day, and welcome to the STERIS PLC First Quarter Fiscal 2021 Conference Call and Webcast.
- (2020-08-05 00:00) Analysis on Impact of COVID-19- Global Explosive Detection Equipment Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Bruker Corp. | Technavio
Summary: The Global Explosive Detection Equipment Market will grow by $2.72 bn during 2020-2024
- (2020-08-06 00:00) Penn State Microbiome Center and GALT Enter Collaboration to Advance Research
Summary: Researchers will utilize GALT's Prospector high-throughput microbial isolation and cultivation system to generate banks of live microbial isolates.
- (2020-08-07 00:00) HighRadius Adds New Leader to Drive Finance Digital Transformation in Growing Enterprise Client Base
Summary: HighRadius, a fintech enterprise Software-as-a-Service (SaaS) company specializing in automating the order-to-cash and treasury management processes,
|
0
|
A
|
2020-08-01 to 2020-08-14
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-08 to 2020-08-14
[Next Week]: 2020-08-14 to 2020-08-21
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-08-14:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-08-08 to 2020-08-14, A's stock price increased from 97.14 to 97.37. News during this period are listed below:
[News]:
- (2020-08-08 00:00) Automated Test Equipment Market Highlights the Impact of COVID-19 2020-2024 | Augmented Production of Electronic Goods to Boost Market Growth | Technavio
Summary: The Global Automated Test Equipment Market will grow by USD 1.47 bn during 2020-2024
- (2020-08-08 02:16) Automated Test Equipment Market Highlights the Impact of COVID-19 2020-2024 | Augmented Production of Electronic Goods to Boost Market Growth | Technavio
- (2020-08-08 02:31) COVID-19 Impacts: PCR System for Food Diagnostics Market will Accelerate at a CAGR of over 8% through 2020-2024 | Rising Foodborne Illnesses to Boost Growth | Technavio
- (2020-08-09 18:44) Brenntag AG (BNTGF) CEO Christian Kohlpaintne on Q2 2020 Results - Earnings Call Transcript
Summary: Brenntag AG. (OTCPK:BNTGF) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Christian Kohlpaintne - Chief Executive Officer Georg Müller - Chief Financial Officer Conference Call Participants Rory McKenzie - UBS Laurent Favre - Exane BNP Paribas Rajesh Kumar - HSBC Markus Mayer - Baader Helvea Steven Goulden - Deutsche Bank Isha Sharma - MainFirst Bank Chetan Udeshi - JPMorgan.
- (2020-08-10 00:00) Laboratory Analytical Instruments and Consumables Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Rising Applications of Analytical Instruments to Boost Market Growth | Technavio
Summary: The Global Laboratory Analytical Instruments and Consumables Market will grow by USD 13.81 bn during 2020-2024
- (2020-08-11 00:00) COVID-19 Impacts: Graphite Electrode Market Will Accelerate at a CAGR of Almost 2% Through 2020-2024 | Increased Demand for High-quality Steel to Boost Growth | Technavio
Summary: The Global Graphite Electrode Market will grow by 182.85 th MT during 2020-2024
- (2020-08-11 01:40) Agilent Technologies (A) to Release Quarterly Earnings on Tuesday
Summary: Agilent Technologies (NYSE:A) will post its quarterly earnings results after the market closes on Tuesday, August 18th. Analysts expect Agilent Technologies to post earnings of $0.66 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link. Agilent Technologies (NYSE:A) last posted its earnings […]
- (2020-08-11 16:49) Charting the approach of record highs, S&P 500 rises amid market rotation
Summary: Technically speaking, the U.S. benchmarks’ already-bullish backdrop has strengthened amid rotational August price action, writes Michael Ashbaugh.
|
1
|
A
|
2020-08-08 to 2020-08-21
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-15 to 2020-08-21
[Next Week]: 2020-08-21 to 2020-08-28
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-08-21:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-08-15 to 2020-08-21, A's stock price increased from 97.51 to 98.30. News during this period are listed below:
[News]:
- (2020-08-18 00:00) A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Walmart Earnings
Summary: Pre-open movers
U.S. stock futures traded slightly higher in early pre-market trade, as investors are awaiting earnings from Walmart Inc (NYSE: WMT), Advance Auto Parts, Inc. (...
- (2020-08-18 08:00) Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to expand state-of-the-art manufacturing capacity for nucleic acid-based therapeutics.
- (2020-08-18 16:05) Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces third quarter fiscal year 2020 financial results.
- (2020-08-18 16:41) Charting a pulling-teeth breakout attempt: S&P 500, Nasdaq challenge record territory
Summary: Technically speaking, the S&P 500 and Nasdaq Composite have registered nominal record highs this week, though a pulling-teeth breakout attempt remains...
- (2020-08-18 21:44) Agilent Technologies Inc. (A) CEO Mike McMullen on Q3 2020 Results - Earnings Call Transcript
Summary: Agilent Technologies Inc. (NYSE:A) Q3 2020 Results Conference Call August 18, 2020 04:30 PM ET Company Participants Ankur Dhingra - VP, IR Mike McMullen - President and CEO Bob McMahon - SVP and CFO Jacob Thaysen - President, Life Sciences & Applied Markets Group Sam Raha - President, Diagnostics and Genomics Group Padraig McDonnell - President, Agilent CrossLab Group Conference Call Participants Doug Schenkel - Cowen Vijay Kumar - Evercore ISI Tycho Peterson - JP Morgan Puneet Souda - Leerink Derik de Bruin - Bank of America Brandon Couillard - Jefferies Dan Leonard - Wells Fargo Catherine Schulte - Baird Steve Willoughby - Cleveland Research Dan Brennan - UBS Patrick Donnelly - Citigroup Jack Meehan - Nephron Research Presentation Operator Good afternoon, and welcome to the Agilent Technologies Third Quarter Earnings Conference Call.
- (2020-08-19 04:46) Agilent Technologies Inc. (A) Q3 2020 Earnings Call Transcript | AlphaStreet
Summary: Final earnings conference call transcript of Agilent Technologies Inc. - A stock
- (2020-08-19 06:40) Wall Street Breakfast: S&P 500 To Take Aim At New Record
Summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- (2020-08-19 12:01) Stocks making the biggest moves in the premarket: Target, Lowe's, J&J, Momenta, Gilead & more
Summary: The stocks making the biggest moves in premarket trading include Target, Lowe's, J&J, Momenta, Gilead, and more.
- (2020-08-19 18:15) Agilent Technologies, Inc. 2020 Q3 - Results - Earnings Call Presentation
Summary: The following slide deck was published by Agilent Technologies, Inc. in conjunction with their 2020 Q3 earnings call..
|
2
|
A
|
2020-08-15 to 2020-08-28
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-22 to 2020-08-28
[Next Week]: 2020-08-28 to 2020-09-04
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-08-28:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-08-22 to 2020-08-28, A's stock price increased from 97.60 to 99.90. News during this period are listed below:
[News]:
- (2020-08-22 00:00) COVID-19 Impacts: Global Metabolomics Market will Accelerate at a CAGR of over 12% through 2020-2024 | Increased Adoption in the Field of Precision Medicine to Boost Growth | Technavio
Summary: The Global Metabolomics Market will grow by $ 1.54 bn during 2020-2024
- (2020-08-25 00:00) Global Anatomic Pathology Market Analysis 2020-2025 - by Product & Service, Consumables, Application, End User and Region - ResearchAndMarkets.com
Summary: The
- (2020-08-25 03:34) $0.91 Earnings Per Share Expected for Agilent Technologies Inc (NYSE:A) This Quarter
Summary: Wall Street analysts expect Agilent Technologies Inc (NYSE:A) to report earnings per share (EPS) of $0.91 for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Agilent Technologies’ earnings. The lowest EPS estimate is $0.85 and the highest is $1.00. Agilent Technologies reported earnings of $0.89 per share during the same […]
- (2020-08-26 00:00) Global Genetic Testing Market Size Forecast to 2023 - ResearchAndMarkets.com
Summary: The
- (2020-08-27 00:00) Agilent Sets the Standard in Customer Flexibility with Analytical Technology Subscription Model
Summary: Agilent Technologies Inc. (NYSE: A) today announced its first-ever instrument subscription program, designed to meet the needs of customers with dynam
- (2020-08-27 06:46) Virtu Financial LLC Buys Shares of 2,379 Agilent Technologies Inc (NYSE:A)
Summary: Virtu Financial LLC acquired a new stake in Agilent Technologies Inc (NYSE:A) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,379 shares of the medical research company’s stock, valued at approximately $210,000. Other institutional investors also recently bought and sold […]
- (2020-08-27 08:00) Agilent Sets the Standard in Customer Flexibility with Analytical Technology Subscription Model
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.
|
-3
|
A
|
2020-08-22 to 2020-09-04
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-29 to 2020-09-04
[Next Week]: 2020-09-04 to 2020-09-11
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-09-04:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-08-29 to 2020-09-04, A's stock price decreased from 100.42 to 96.84. News during this period are listed below:
[News]:
- (2020-08-31 13:45) Pershing Square Holdings Semi-Annual Letter To Shareholders
Summary: Pershing Square Holdings, Ltd. is a closed-ended investment company.
- (2020-09-01 08:00) Agilent Announces SureSelect XT HS2 RNA Reagent Kit, a Library Prep and Target Enrichment Solution for RNA-Seq
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.
- (2020-09-02 10:23) Tracking Bill Ackman's Pershing Square Portfolio - Q2 2020 Update
Summary: Bill Ackman’s 13F portfolio value increased from $6.57B to $7.75B this quarter. Pershing Square increased Restaurant Brands while dropping Berkshire Hathaway during the quarter.
|
2
|
A
|
2020-08-29 to 2020-09-11
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-09-05 to 2020-09-11
[Next Week]: 2020-09-11 to 2020-09-18
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-09-11:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-09-05 to 2020-09-11, A's stock price increased from 95.14 to 98.60. News during this period are listed below:
[News]:
- (2020-09-05 08:21) Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
Summary: Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- (2020-09-06 04:42) Wall Street Breakfast: The Week Ahead
Summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- (2020-09-11 10:49) Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
Summary: Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.
|
1
|
A
|
2020-09-05 to 2020-09-18
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-09-12 to 2020-09-18
[Next Week]: 2020-09-18 to 2020-09-25
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-09-18:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-09-12 to 2020-09-18, A's stock price remained roughly flat from 99.42 to 99.38. News during this period are listed below:
[News]:
- (2020-09-15 00:00) Spectrophotometer Market: COVID-19 Business Continuity Plan | Evolving Opportunities With Agilent Technologies Inc. and Avantor Inc. | Technavio
Summary: The Global Spectrophotometer Market will grow by $ 869.24 mn during 2020-2024
- (2020-09-16 00:00) In Vitro Diagnostic (IVD) Reagents (Antibodies, Oligonucleotide, Nucleic Acid Probe) Market - Global Forecast to 2027 - ResearchAndMarkets.com
Summary: The
- (2020-09-16 16:05) Agilent Announces Cash Dividend of 18 Cents Per Share
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces dividend of 18 cents per share.
- (2020-09-17 00:00) Chromatography Market- Roadmap for Recovery from COVID-19 | Growing Demand For Portable Analytical Systems to boost the Market Growth | Technavio
Summary: The Global Chromatography Market will grow by $ 4.13 bn during 2020-2024
- (2020-09-17 06:30) Agilent Technologies Inc (NYSE:A) Shares Sold by Fmr LLC
Summary: Fmr LLC decreased its stake in shares of Agilent Technologies Inc (NYSE:A) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 353,733 shares of the medical research company’s stock after selling 18,800 shares during the quarter. Fmr LLC owned about 0.11% […]
- (2020-09-17 08:00) Agilent Expands Line of Innovative Flow Cytometers with the NovoCyte Penteon
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.
- (2020-09-17 14:17) Tracking William Nygren's Harris Associates Portfolio - Q2 2020 Update (MUTF:OAKMX)
Summary: Harris Associates 13F portfolio value increased from $36.11B to $41.11B this quarter. They increased Workday while reducing Regeneron Pharmaceuticals.
|
-2
|
A
|
2020-09-12 to 2020-09-25
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-09-19 to 2020-09-25
[Next Week]: 2020-09-25 to 2020-10-02
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-09-25:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-09-19 to 2020-09-25, A's stock price decreased from 98.13 to 97.69. News during this period are listed below:
[News]:
- (2020-09-21 00:00) Laboratory Equipment Services Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
Summary: The Laboratory Equipment Services market will register an incremental spend of about $24 billion, growing at a CAGR of 6.23%.
- (2020-09-21 08:22) AdvisorNet Financial Inc Has $113,000 Position in Agilent Technologies Inc (NYSE:A)
Summary: AdvisorNet Financial Inc reduced its position in shares of Agilent Technologies Inc (NYSE:A) by 10.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,282 shares of the medical research company’s stock after selling 148 shares during the period. AdvisorNet Financial Inc’s […]
- (2020-09-22 00:00) Instrumentation Services Market: COVID-19 Business Continuity Plan | Evolving Opportunities With ABB Ltd. and Agilent Technologies Inc. | Technavio
Summary: The Global Instrumentation Services Market will grow by $ 1.31 bn during 2020-2024
- (2020-09-22 16:05) Quantum Genomics :
Quantum Genomics conclut un accord de licence et de collaboration exclusif avec Orient EuroPharma (OEP) | Zone bourse
- (2020-09-23 00:00) COVID-19 Recovery Analysis: Explosive Detection Equipment Market | Enhanced Security Mandate of Authorities to Boost the Market Growth | Technavio
Summary: The Global Explosive Detection Equipment Market will grow by $ 2.72 bn during 2020-2024
- (2020-09-25 00:00) Insights on the Predictive and Presymptomatic Testing Global Market to 2027 - Featuring Mapmygenome, Myriad Genetics & Pathway Genomics Among Others - ResearchAndMarkets.com
Summary: The
|
2
|
A
|
2020-09-19 to 2020-10-02
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-09-26 to 2020-10-02
[Next Week]: 2020-10-02 to 2020-10-09
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-02:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-09-26 to 2020-10-02, A's stock price increased from 99.51 to 100.01. News during this period are listed below:
[News]:
- (2020-09-29 00:00) COVID-19 Recovery Analysis: Protein Expression Market | Increasing Advances in Proteomics Research to Boost Market Growth | Technavio
Summary: The Global Protein Expression Market will grow by $ 1.63 bn during 2020-2024
- (2020-09-30 00:00) Global Laboratory Centrifuge Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
Summary: The Global Laboratory Centrifuge market will register an incremental spend of about $292 million, growing at a CAGR of 3.42%
- (2020-10-02 00:00) Global Single Cell Genomics Markets, 2020-2024 with COVID-19 Updates (Q3 2020) - ResearchAndMarkets.com
Summary: The
|
6
|
A
|
2020-09-26 to 2020-10-09
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-03 to 2020-10-09
[Next Week]: 2020-10-09 to 2020-10-16
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-09:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-03 to 2020-10-09, A's stock price increased from 103.12 to 105.76. News during this period are listed below:
[News]:
- (2020-10-06 00:00) Cell Isolation Market to reach USD 9.47 bn by 2024, Agilent Technologies Inc. and Becton, Dickinson and Co. emerge as Key Contributors to Growth| Technavio
Summary: The Global Cell Isolation Market will grow by USD 9.47 bn during 2020-2024
- (2020-10-06 00:00) Wellcome Sanger Institute selecciona a Arima Genomics como su socio tecnológico de HiC; la compañía anuncia un programa de acceso temprano para la tecnología HiC de alta cobertura
Summary: Arima Genomics, Inc., una compañía de biotecnología que tiene como objetivo acelerar la adopción de la información de la estructura del genoma, anunci
- (2020-10-06 11:15) Disruptive Technologies Are Enabling The Re-Opening Economy
Summary: Sandwiched between the two extremes of the largely shut-down Stay-at-Home Economy and a fully opened New Normal Economy, the Re-Opening Economy is an uncertain, transitional phase.
- (2020-10-07 00:00) COVID-19 Impact and Recovery Analysis | Laboratory Equipment Services Market Procurement Intelligence Report Forecasts Spend Growth of Over USD 24 Billion | SpendEdge
Summary: Global Laboratory Equipment Services Market is poised to experience spend growth of more than USD 24 billion between 2020-2024 at a CAGR of over 6.23%
- (2020-10-07 09:38) Global Womens Health Diagnostics Market Investment Feasibility 2029 With Top Manufactures - Agilent Technologies, Ariosa Diagnostics
Summary: Oct 07, 2020 (WiredRelease via Comtex) --
Radical Growth of Global Womens Health Diagnostics Market Provides an updated and current analysis of the...
- (2020-10-08 00:00) Global Biosensors in Life Sciences Market Will Showcase Neutral Impact During 2020-2024 | Advantages of Biosensors in Drug Analysis to Boost Market Growth | Technavio
Summary: The Global Biosensors in Life Sciences Market will grow by $ 2.32 bn during 2020-2024
- (2020-10-08 07:56) Fulton Bank N. A. Has $654,000 Stock Position in Agilent Technologies Inc (NYSE:A)
Summary: Fulton Bank N. A. grew its holdings in shares of Agilent Technologies Inc (NYSE:A) by 17.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,480 shares of the medical research company’s stock after buying an additional 957 shares during the quarter. […]
- (2020-10-08 07:56) Agilent Technologies Inc (NYSE:A) Shares Sold by First Hawaiian Bank
Summary: First Hawaiian Bank trimmed its holdings in shares of Agilent Technologies Inc (NYSE:A) by 2.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,496 shares of the medical research company’s stock after selling 336 shares during the quarter. First Hawaiian Bank’s holdings in […]
- (2020-10-08 10:32) Agilent Announces the Availability of Objective Decision Support for Pathologists Reviewing Breast Cancer Cases
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the expansion of Visiopharm’s validated image analysis algorithm to incorporate HercepTest™ mAb pharmDx for Dako Omnis, both CE-IVD marked and recently released for sale in Europe. This development enables pathologists to use the Visiopharm HER2 APP for objective decision support in the assessment of HercepTest™ mAb pharmDx stained slides, saving valuable time for both pathologists and patients. The Hercep
- (2020-10-09 00:00) Genomics Market| Need for Creating/Upgrading Genome Databases to Boost the Market Growth | Technavio
Summary: The Global Genomics Market will grow by USD 17.23 bn during 2020-2024
|
1
|
A
|
2020-10-03 to 2020-10-16
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-10 to 2020-10-16
[Next Week]: 2020-10-16 to 2020-10-23
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-16:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-10 to 2020-10-16, A's stock price increased from 105.43 to 106.70. News during this period are listed below:
[News]:
- (2020-10-12 00:00) Top Sector ETFs From Wall Street's Best Week in 3 Months
Summary: Stocks Analysis by Zacks Investment Research covering: S&P 500, Xilinx Inc, NVIDIA Corporation, Advanced Micro Devices Inc. Read Zacks Investment Research's latest article on Investing.com
- (2020-10-13 00:00) DNA Sequencing Market to Reach $ 12.5 bn by 2024, Agilent Technologies Inc., BGI Genomics Co. Ltd., and Thermo Fisher Scientific Inc., Emerge as Key Contributors to Growth | Technavio
Summary: The Global DNA Sequencing Market will grow by USD 12.5 bn during 2020-2024
- (2020-10-13 09:14) Agilent Technologies Inc (NYSE:A) Stock Position Increased by LGT Capital Partners LTD.
Summary: LGT Capital Partners LTD. increased its stake in shares of Agilent Technologies Inc (NYSE:A) by 3.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 829,680 shares of the medical research company’s stock after purchasing an additional 26,210 shares during the period. Agilent Technologies makes […]
- (2020-10-14 08:00) Agilent Early Career Professor Award Presented to Carl DeSelm
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Carl DeSelm, M.D., Ph.D., has received the 2020 Agilent Early Career Professor Award. Dr. DeSelm is an assistant professor of Radiation Oncology at the Washington University School of Medicine in St. Louis, MO. This years’ award topic is cellular engineering and analysis—a field that greatly impacts Agilent customers. The DeSelm lab’s current research focuses on the engineering and clinical developmen
- (2020-10-14 08:14) Agilent Technologies Inc (NYSE:A) Shares Acquired by Envestnet Asset Management Inc.
Summary: Envestnet Asset Management Inc. grew its stake in Agilent Technologies Inc (NYSE:A) by 10.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 256,741 shares of the medical research company’s stock after purchasing an additional 24,832 shares during the period. Envestnet Asset […]
- (2020-10-15 00:00) Global Treatment and Diagnosis of Sexually Transmitted Diseases Markets, 2025 - Focus on Antibiotics, Antivirals/Antiretrovirals & EIA, ELISA, PCR, Rapid Diagnostics - ResearchAndMarkets.com
Summary: The
- (2020-10-15 08:00) Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Agilent Vaya Raman raw material identity verification system has received a 2020 R&D 100 Award in the Analytical/Test category. The worldwide competition, held by R&D World, recognizes R&D pioneers and their revolutionary contributions to science and technology. Agilent’s award-winning product is the first handheld Raman spectrometer incorporating spatially offset Raman spectroscopy (S
- (2020-10-16 00:00) Global Capillary Electrophoresis Market|Increasing R&D Expenditure to Boost Market Growth | Technavio
Summary: The Global Capillary Electrophoresis Market will grow by $ 300.97 mn during 2020-2024
- (2020-10-16 07:22) Regentatlantic Capital LLC Sells 474 Shares of Agilent Technologies Inc (NYSE:A)
Summary: Regentatlantic Capital LLC cut its holdings in Agilent Technologies Inc (NYSE:A) by 7.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,768 shares of the medical research company’s stock after selling 474 shares during the quarter. Regentatlantic Capital LLC’s holdings in […]
- (2020-10-16 08:16) CX Institutional Purchases 299 Shares of Agilent Technologies Inc (NYSE:A)
Summary: CX Institutional lifted its position in shares of Agilent Technologies Inc (NYSE:A) by 130.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 528 shares of the medical research company’s stock after acquiring an additional 299 shares during the period. CX […]
|
0
|
A
|
2020-10-10 to 2020-10-23
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-17 to 2020-10-23
[Next Week]: 2020-10-23 to 2020-10-30
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-23:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-17 to 2020-10-23, A's stock price increased from 105.49 to 106.17. News during this period are listed below:
[News]:
- (2020-10-18 00:00) COVID-19 Impact and Recovery Analysis |Laboratory Equipment Services Market Procurement Intelligence Report Forecasts Spend Growth of over USD 24 Billion
Summary: Laboratory Equipment Services Market is poised to experience spend growth of more than USD 24 billion between 2020-2024 at a CAGR of over 6.23%.
- (2020-10-18 04:58) Nachman Norwood & Parrott Inc Makes New Investment in Agilent Technologies Inc (NYSE:A)
Summary: Nachman Norwood & Parrott Inc purchased a new position in Agilent Technologies Inc (NYSE:A) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 515 shares of the medical research company’s stock, valued at approximately $52,000. A number of other institutional investors and hedge funds […]
- (2020-10-19 00:00) Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020
Summary: Agilent Technologies Inc. (NYSE: A) today announced that their 1220, 1260, and 1290 Infinity II LC product families have received the My Green Lab acc
- (2020-10-19 06:00) QUANTUM GENOMICS : Quantum Genomics conclut un accord de licence et de collaboration exclusif avec Qilu Pharmaceutical
Summary: Quantum Genomics recevra jusqu'à 50 M$ de paiements initiaux (upfront) et d'étapes (milestones) ainsi que des royalties à deux chiffres sur les ventes futures.
Qilu Pharmaceutical recevra une licence exclusive pour développer et commercialiser le firibastat pour le traitement de l'hypertension difficile à traiter / résistante en Chine, y compris Hong-Kong et Macao
- (2020-10-19 06:05) Quantum Genomics :
Quantum Genomics conclut un accord de licence et de collaboration exclusif avec Qilu Pharmaceutical | Zone bourse
- (2020-10-19 06:18) Mission Wealth Management LP Buys 101 Shares of Agilent Technologies, Inc. (NYSE:A)
Summary: Mission Wealth Management LP increased its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 1.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,539 shares of the medical research company’s stock after acquiring an additional 101 shares during the quarter. Mission […]
- (2020-10-19 07:38) Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that their 1220, 1260, and 1290 Infinity II LC product families have received the My Green Lab accountability, consistency, and transparency (ACT) certification. Recognition of these products by My Green Lab highlights Agilent's commitment to pursuing sustainability throughout the production and lifecycle of its analytical equipment. Agilent will showcase these accredited products at the 2020 analytica vir
- (2020-10-20 00:00) Validation of Bluestar Genomics’ Technology for Non-Invasive Detection of Pancreatic Cancer Published in Nature Communications
Summary: Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, announced today t
- (2020-10-20 06:40) Agilent Technologies, Inc. (NYSE:A) Shares Purchased by IBM Retirement Fund
Summary: IBM Retirement Fund boosted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 39.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,053 shares of the medical research company’s stock after buying an additional 2,821 shares during […]
- (2020-10-22 07:41) Pacer Advisors Inc. Sells 4,329 Shares of Agilent Technologies, Inc. (NYSE:A)
Summary: Pacer Advisors Inc. lowered its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 13.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,835 shares of the medical research company’s stock after selling 4,329 shares during the quarter. Pacer Advisors Inc.’s holdings in Agilent […]
|
-4
|
A
|
2020-10-17 to 2020-10-30
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-24 to 2020-10-30
[Next Week]: 2020-10-30 to 2020-11-06
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-30:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-24 to 2020-10-30, A's stock price decreased from 104.63 to 102.09. News during this period are listed below:
[News]:
- (2020-10-26 17:15) Bill Ackman Reduces Lowe's, Agilent Technologies and Hilton Worldwide Holdings
Summary: Bill Ackman (Trades, Portfolio), leader of Pershing Square Capital Management, has revealed his portfolio for the third quarter.
- (2020-10-29 15:00) Agilent to Webcast Fourth-Quarter Fiscal Year 2020 Financial Results Presentation, Sets Date for Virtual Analyst and Investor Meeting
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent will release fiscal fourth quarter financial results Mon., Nov. 23. and will also host a virtual analyst and investor event Wed., Dec. 9.
- (2020-10-29 15:00) Agilent to Webcast Fourth-Quarter Fiscal Year 2020 Financial Results Presentation, Sets Date for Virtual Analyst and Investor Meeting
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release fourth-quarter fiscal year 2020 financial results after the stock market closes on Monday, Nov. 23. The company will host a live webcast of its investor conference call in listen-only mode on the same day. The company will also host an Analyst and Investor meeting on Wednesday, Dec. 9. The meeting, which will be conducted in a virtual format, will include presentations by Agilent’s senior management team on the company’s long-range strategies for accelerating revenue growth and shareholder value creation. The meeting will include a live question and answer session following the presentations. Details for both webcasts: Agilent Fourth-Quarter Earnings Webcast Monday, Nov. 23, 2020 at 1:30 p.m. Pacific time Agilent 2020 Virtual Analyst and Investor Meeting Wednesday, Dec. 9, 2020 at 7 a.m. Pacific time Links to the events will be provided in the “News & Events -- Events” portion of the Investor Relations section of the Agilent website. The webcasts will remain on the company site for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.
|
10
|
A
|
2020-10-24 to 2020-11-06
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-31 to 2020-11-06
[Next Week]: 2020-11-06 to 2020-11-13
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-11-06:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-31 to 2020-11-06, A's stock price increased from 105.24 to 112.54. News during this period are listed below:
[News]:
- (2020-11-04 08:00) Agilent Collaborates With SGS to Release New US EPA Method for the Analysis of Dioxins Using GC/TQ
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today a collaboration with SGS has resulted in a new GC/TQ method, the SGS AXYS Method 16130, approved by the US EPA as an alternative method for the future regulation and detection of dioxins. Dioxins are a group of chemical compounds that are considered persistent environmental pollutants and subsequently find their way into the food chain. These chemicals are listed as persistent organic pollutants under the
|
-2
|
A
|
2020-10-31 to 2020-11-13
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-11-07 to 2020-11-13
[Next Week]: 2020-11-13 to 2020-11-20
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-11-13:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-11-07 to 2020-11-13, A's stock price decreased from 112.50 to 110.17. News during this period are listed below:
[News]:
No relevant company news reported during this week.
|
1
|
A
|
2020-11-07 to 2020-11-20
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-11-14 to 2020-11-20
[Next Week]: 2020-11-20 to 2020-11-27
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-11-20:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-11-14 to 2020-11-20, A's stock price increased from 110.27 to 110.89. News during this period are listed below:
[News]:
- (2020-11-17 08:32) Agilent Presents Thought Leader Award to Drs. Carl H. June and Michael Milone
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced professors Carl H. June, MD, and Michael Milone, MD, Ph.D., as recipients of an Agilent Thought Leader Award. Both scientists are being recognized for their joint contributions to the field of CAR T-cell mediated cancer immunotherapy, having codeveloped tisagenlecleucel (Kymriah™), the first cell and gene therapy product approved by the US FDA. The award will focus on defining standards for the design, val
- (2020-11-18 16:05) Agilent Increases Cash Dividend to 19.4 Cents Per Share
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent increases the company's quarterly dividend to 19.4 cents per share of common stock, reflecting an 8% increase over the previous quarter.
|
3
|
A
|
2020-11-14 to 2020-11-27
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-11-21 to 2020-11-27
[Next Week]: 2020-11-27 to 2020-12-04
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-11-27:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2020-11-21 to 2020-11-27, A's stock price increased from 112.21 to 114.09. News during this period are listed below:
[News]:
- (2020-11-23 08:00) Agilent Launches New NanoDis System for Nanoparticle Dissolution Testing
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of the NanoDis System for nanoparticle dissolution testing. Combining Agilent instrumentation and software to enable customers to meet 21 CFR Part 11 and other regulations through its application, the new NanoDis System delivers a dedicated workflow that is automatable and auditable. Designed in collaboration with Dr. Emre Türeli from nanoparticle manufacturer MyBiotech GmbH, the NanoDis S
- (2020-11-23 09:00) Dividend Changes: November 14-20, 2020
Summary: In this article series, we provide a weekly summary of dividend changes. A summary table provides relevant data and key statistics of dividend increases.
- (2020-11-23 16:05) Agilent Reports Fourth-Quarter and Fiscal Year 2020 Financial Results; Initiates Fiscal 2021 Guidance
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent reports fourth-quarter and fiscal year 2020 financial results; initiates fiscal 2021 guidance.
- (2020-11-23 16:29) Agilent Technologies: Q4 Earnings Insights
Summary: Shares of Agilent Technologies (NYSE:A) fell 2.53% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 10.11% over the past year to $0.98, which beat the estimate of $0.93.
- (2020-11-23 20:15) Agilent Technologies Inc. (A) CEO Mike McMullen on Q4 2020 Results - Earnings Call Transcript
Summary: Agilent Technologies Inc. (A) CEO Mike McMullen on Q4 2020 Results - Earnings Call Transcript
|
1
|
A
|
2020-11-21 to 2020-12-04
|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-11-28 to 2020-12-04
[Next Week]: 2020-12-04 to 2020-12-11
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-12-04:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2020-11-28 to 2020-12-04, A's stock price decreased from 116.90 to 115.15. News during this period are listed below:
[News]:
- (2020-11-30 08:00) Agilent Announces Launch of Global Biomarker Pathologist Training Program
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and confidently. Developed by Agilent – a worldwide leader in developing and commercializing diagnostic products – this training program incorporates Agilent's unique expertise in companion diagnostics and partnership with top pharmaceutical companies. Biomarker testi
- (2020-12-02 08:00) Agilent Announces New, Innovative 7850 ICP-MS System
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a new ICP-MS instrument, the Agilent 7850 ICP-MS System, that provides new smart tools to minimize common time traps that can affect ICP-MS analysis workflows. Building on decades of innovation, the 7850 ICP-MS combines market-leading performance with new smart software features that bring advanced capabilities to the routine ICP-MS laboratory. The new 7850 provides solutions that enable customers to be mo
|
3
|
A
|
2020-11-28 to 2020-12-11
|
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 624